Experimental CAR-T therapy targets tough autoimmune conditions
NCT ID NCT07604792
First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BCMA/CD19 bispecific CAR-T cells
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases.
- What could go wrong
- This is a very early, small trial with only 9 participants, so results may not apply widely. CAR-T therapy carries risks like cytokine release syndrome and neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Gaobo Boren Hospital Co., Ltd
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?
- Can engineered immune cells tame autoimmune disease?
- Blood test may spot hidden nerve damage behind chronic constipation
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?